Clinical Trial Update: Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating an increased dose GnRH antagonist for coasting to lower ovarian hyperstimulation syndrome risk has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Hyperstimulation Syndrome

Drugs mentioned

• GnRH antagonist

Snippet

Sponsor: Wolfson Medical Center | Conditions: Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS) | Phase 1, Phase 2 | Status: WITHDRAWN